• Avid Technology Now Covered by Analysts at StockNews.com

    8 days ago - By ETF Daily News

    StockNews.com initiated coverage on shares of Avid Technology in a report issued on Thursday. The brokerage set a “buy” rating on the technology company's stock. AVID has been the subject of a number of other reports. Rosenblatt Securities reiterated a “neutral” rating and set a $28.00 target price on shares of...
    Read more ...

     

  • Atlanticus Coverage Initiated by Analysts at StockNews.com

    8 days ago - By ETF Daily News

    StockNews.com started coverage on shares of Atlanticus in a note issued to investors on Thursday. The brokerage set a “buy” rating on the credit services provider's stock. Separately, JMP Securities cut their price objective on Atlanticus from $50.00 to $42.00 and set a “market outperform” rating for the company in a...
    Read more ...

     

  • AMERISAFE Now Covered by StockNews.com

    8 days ago - By ETF Daily News

    Equities researchers at StockNews.com initiated coverage on shares of AMERISAFE in a research note issued to investors on Thursday. The firm set a “hold” rating on the insurance provider's stock. Several other brokerages have also recently issued reports on AMSF. TheStreet upgraded shares of AMERISAFE from a “c+” rating to a...
    Read more ...

     

  • Activision Blizzard Earns Hold Rating from Analysts at StockNews.com

    8 days ago - By ETF Daily News

    Research analysts at StockNews.com assumed coverage on shares of Activision Blizzard in a research report issued to clients and investors on Thursday. The firm set a “hold” rating on the stock. Several other equities analysts have also recently weighed in on ATVI. Wells Fargo & Company upgraded Activision Blizzard from an...
    Read more ...

     

  • StockNews.com Initiates Coverage on Aurinia Pharmaceuticals

    8 days ago - By ETF Daily News

    Research analysts at StockNews.com started coverage on shares of Aurinia Pharmaceuticals in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the biotechnology company's stock. Separately, Royal Bank of Canada reaffirmed an “outperform” rating and set a $11.00 price target on shares...
    Read more ...